Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

33.44
+0.41001.24%
Post-market: 33.440.00000.00%19:30 EDT
Volume:396.18K
Turnover:13.26M
Market Cap:1.02B
PE:-51.12
High:34.09
Open:33.00
Low:32.89
Close:33.03
52wk High:44.28
52wk Low:17.72
Shares:30.55M
Float Shares:28.22M
Volume Ratio:1.09
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6542
EPS(LYR):-0.8334
ROE:-4.20%
ROA:-1.36%
PB:2.17
PE(LYR):-40.12

Loading ...

Castle Biosciences Announces New York State Department of Health Approval of Its Advancead-tx™ Test

THOMSON REUTERS
·
Jul 15

Castle Biosciences Schedules Second-quarter Results Webcast

Reuters
·
Jul 09

Castle Biosciences COO Kristen Oelschlager Sells 8,586 Shares for $209,041.2

Reuters
·
Jul 07

Castle Biosciences Says Decisiondx-melanoma I31-slnb Beats MIA Nomogram in Prospective SLNB Risk Study

Reuters
·
Jun 26

Castle Biosciences Initiated at Buy by Roth Capital

Dow Jones
·
Jun 25

Roth starts Castle Biosciences at Buy, notes quality revenue growth outlook

TIPRANKS
·
Jun 25

Castle Biosciences CFO Frank Stokes set for Houston Business Journal CFO Awards event

Reuters
·
Jun 23

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

THOMSON REUTERS
·
Jun 23

Castle Biosciences grants 204,925 inducement RSUs to 172 employees under 2022 plan

Reuters
·
Jun 19

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 19

Castle Biosciences COO Kristen Oelschlager sells 8,587 shares worth $177,230.77

Reuters
·
Jun 19

Castle Biosciences CEO Derek J. Maetzold reports disposal of common shares worth $43,371.58

Reuters
·
Jun 18

Castle Biosciences says TissueCypher Barrett’s esophagus test tops 100,000 orders

Reuters
·
Jun 16

SciBase, Castle Biosciences enroll first patient in DETECT-AD study testing EIS to predict atopic dermatitis flares

Reuters
·
Jun 10

Castle Biosciences CEO Derek Maetzold disposes of common shares worth $129,609.50

Reuters
·
Jun 04

Castle Biosciences shareholders elect three directors at annual meeting

Reuters
·
May 30

Castle Biosciences price target lowered to $35 from $50 at KeyBanc

TIPRANKS
·
May 29

SEALSQ's QS7001 Post-Quantum Secure Element Achieves NIST SP 800-90B Entropy Source Validation, key milestone Toward FIPS 140-3 and Common Criteria EAL5+ Certification

GlobeNewswire
·
May 28

Castle Bio CEO Derek Maetzold disposes 4,477 shares worth $90,130.11

Reuters
·
May 23

Castle Biosciences to present at Jefferies Global Healthcare Conference

Reuters
·
May 13